EPISODE 13 | 12 MIN | 27 Apr. 2022
Weekly Pharma News Review (0418-0424)
EPISODE 13 | 12 MIN | 27 Apr. 2022
#Drug Review #R&D #Business
Weekly Pharma News Review (0418-0424)
Play
Summary
The Virtual Expo Connect event of CPhI & P-MEC China was fully launched on April 21. Speakers from Bachem guested on the VEC webinar and shared their experience and insight on how to partner with an experienced CDMO to meet peptide and oligonucleotide drug developers’ manufacturing needs. While in the last week’s Chinese pharma market, Ascletis said that in antiviral cellular assays, the antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a compound found in Pfizer's Paxlovid. The data suggested that its drug ASC11 showed the potential to be an effective treatment for COVID-19.
Timeline
1
PART1 | 00:12
VEC webinar: Trends in Peptides and Oligonucleotides - Choosing a Partner CDMO
2
PART2 | 01:12
Hengrui Medicine announced the filing of a marketing application for irinotecan hydrochloride liposome injection
3
PART3 | 01:42
KingstronBio's in-house R&D cardiac surgical biological patch Elite Air was approved for marketing
4
PART4 | 02:01
A teriparatide injection from Salubris was approved for marketing
5
PART5 | 02:27
The procarbazine hydrochloride capsule of Zhaoke Pharmaceutical was approved for marketing
6
PART6 | 02:52
Qilu Pharmaceutical's clinical application for oseltamivir phosphate oral soluble film was accepted
7
PART7 | 03:27
A new clinical trial application of Daiichi Sankyo's U3-1402 was submitted
8
PART8 | 03:55
Blueprint Medicines and Zai Lab jointly submitted a clinical trial application for BLU-945 capsules
9
PART9 | 04:28
Beihai Biotech has been approved to carry out a Phase II clinical research of their BH011 injection
10
PART10 | 04:51
3D Medicines get the approval of its Phase 1b/2 clinical trial application for 3D229 injection in combination with either envafolimab monoclonal antibody injection or lenvatinib
11
PART11 | 05:19
The first-in-class MK-6024 injection applicated by MSD was approved for clinical in China
12
PART12 | 05:42
Gloria Pharmaceuticals' LAG-3 monoclonal antibody was first approved for clinical trials
13
PART13 | 06:07
XPH announced that TAEST1901 injection was approved for clinical use
14
PART14 | 06:35
NBTXR3 obtained an implied license for the clinical trials, proposing to treat head and neck squamous cell carcinoma
15
PART15 | 07:00
The Phase I clinical trial application, in which relmacabtagene autoleucel injection is used to treat r/r B-ALL in children and young adults, was approved
16
PART16 | 07:29
HAISCO announced the approval of HSK29116's clinical trial application in the U.S.
17
PART17 | 08:01
AstraZeneca and Daiichi Sankyo announced that the new indication marketing application for DS-8201 has been accepted and granted priority review
18
PART18 | 08:34
Sidansai announced that GCC19 CART had been granted the Fast Track by FDA
19
PART19 | 09:11
Ascletis released the preclinical data of ASC11 in COVID-19 that the antiviral potency of ASC11 is 31-fold of that of Nirmatrelvir
20
PART20 | 09:36
Innovent and Eli Lilly jointly announced the release of the interim analysis of the large Phase III research of Sintilimab Injection in combination with chemotherapy
21
PART21 | 10:07
Junshi Biosciences and Vigonvita's VV116 tablet was registered and started a head-to-head Phase III clinical trial versus Pfizer's Paxlovid
22
PART22 | 10:38
Betta started a Phase III clinical trial for Ensartinib
23
PART23 | 11:04
Roche Pharmaceuticals China entered into a collaboration agreement with Teva Pharmaceuticals
You can listen and/or download the episode on Podbean, or directly through iTunes, GooglePlay, Amazon Music and Samsung Podcasts. You can also subscribe our podcast by RSS feed, please copy the full URL below.
RSS Feed:
https://feed.podbean.com/PharmaSources/feed.xml
https://feed.podbean.com/PharmaSources/feed.xml
Copy Feed
Full Transcript